# Teva Pharmaceutical Industries Limited > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Teva Pharmaceutical Industries Limited). ## Overview Teva Pharmaceutical Industries Ltd. is a biopharmaceutical company built around a large global generics platform and a portfolio of branded innovative medicines. It operates through three regional segments — the United States, Europe and International Markets — and also sells active pharmaceutical ingredients, provides contract manufacturing services, and licenses products through its Medis affiliate. ## Products & services • Generic prescription medicines • Innovative medicines in neuroscience and immunology • Biosimilars and OTC products • Active pharmaceutical ingredients (API) • Contract manufacturing services • Out-licensing through Medis - **Generic medicines** (55%) — Off-patent prescription products sold across multiple dosage forms and therapeutic areas. - **Innovative medicines** (25%) — Branded specialty therapies focused on CNS, migraine, MS, respiratory and oncology. - **Biosimilars and OTC** (10%) — Biologic follow-on products and over-the-counter medicines sold in regional markets. - **API and contract manufacturing** (5%) — Third-party active ingredient sales and manufacturing services. - **Out-licensing and other activities** (5%) — Product licensing and affiliate-based commercialization activities. - Generic prescription medicines - Innovative medicines in neuroscience and immunology - Biosimilars and OTC products - Active pharmaceutical ingredients (API) - Contract manufacturing services - Out-licensing through Medis ## Customers Teva sells primarily to wholesalers, retail drug chains, mail-order distributors, managed care purchasing organizations and hospitals. Its customer base differs by product type: generics are sold into large purchasing channels with strong bargaining power, while innovative medicines are sold through specialty and pharmacy distribution channels serving patients with chronic or complex conditions. - **U.S. retail drug chains and wholesalers** (primary) — Buy large volumes of generic medicines and some branded products for broad pharmacy distribution. - **Managed care and buying groups** (primary) — Influence formulary access, rebates and pricing for U.S. medicines. - **Mail-order and specialty distributors** (secondary) — Purchase chronic and specialty therapies such as CNS and migraine products. - **Hospitals and healthcare institutions** (secondary) — Buy injectable, inhaled and other hospital-administered products. - **International pharmacy and healthcare channels** (secondary) — Buy generics, OTC and branded medicines across Europe and other markets. - Retail drug chains buy high-volume generics for pharmacy shelves - Wholesalers distribute both generics and branded medicines - Mail-order distributors purchase repeat-use chronic therapies - Managed care organizations influence formulary access and pricing - Hospitals buy injectable and specialty products for inpatient use ## Geography Teva is headquartered in Israel and operates across 57 markets, with major commercial presence in the United States, Europe and International Markets. The United States and Europe are the most important operating regions, while manufacturing, R&D and commercial activities are distributed globally to support local market access and supply reliability. - **United States** (0%) — One of three operating segments; share not disclosed in provided excerpts - **Europe** (0%) — One of three operating segments; share not disclosed in provided excerpts - **International Markets** (0%) — Broad segment across markets outside the U.S. and Europe; share not disclosed - Headquartered in Israel with global operations across 57 markets - United States is a core market for generics and branded specialty drugs - Europe is a major region for generics, respiratory and migraine products - International Markets covers many countries outside the U.S. and Europe - Global footprint supports local regulatory approvals and supply continuity ## Strategy Teva’s strategy centers on growing its innovative portfolio while using its generics platform, global scale and regional operating structure to support access and lifecycle management. The company also emphasizes capital allocation toward higher-value activities and operational simplification to improve execution, supply reliability and cost efficiency. - **Expand innovative medicines** (medium-term) — Branded specialty products provide differentiation beyond commoditized generics. - **Protect and refresh the generics portfolio** (short-term) — Generics remain the volume base and support broad market access. - **Improve operating efficiency** (short-term) — A simpler cost structure helps fund R&D and commercial execution. - **Broaden geographic execution** (medium-term) — Regional diversification reduces dependence on any single market. - Grow innovative medicines in CNS, migraine and immunology - Use generics scale to support cash generation and market access - Align capital toward highest-value products and programs - Optimize operations and external spend across the global footprint - Expand approvals and launches in Europe and other markets ## Risks Teva is exposed to intense generic-drug competition, customer concentration and pricing pressure, especially in the United States where a few large buyers control much of the market. It also faces regulatory, litigation, cybersecurity and policy risks that can disrupt product approvals, commercialization and supply continuity. - **Generic price erosion and competition** [high] — Off-patent medicines face frequent entry from rival manufacturers and rapid pricing pressure. - **Customer concentration in the U.S.** [high] — A relatively small number of wholesalers, chains and buying groups account for a large share of sales. - **Regulatory and compliance actions** [high] — Pharmaceutical manufacturing and marketing are heavily regulated and noncompliance can trigger penalties or shutdowns. - **Litigation and patent disputes** [medium] — Product challenges, including COPAXONE-related disputes, can delay or limit commercialization. - **Cybersecurity and data security incidents** [medium] — IT disruption or data theft could interrupt operations and create liability. - Generic competition can erode prices and volumes quickly - Large U.S. customers have strong bargaining power - Regulatory actions can delay or block approvals and sales - Litigation and product disputes can restrict commercialization - Cyberattacks could disrupt operations and expose data ## Accounting Teva’s reported results are affected by significant estimates in U.S. revenue deductions, including rebates, chargebacks and sales allowances recorded against gross product sales. Investors should also watch contingencies, income taxes, impairment testing and hedging effects, since these areas can materially change reported earnings and balance-sheet values. - **Revenue recognition and U.S. sales deductions** — Affects reported net revenue and comparability across quarters - **Contingencies and litigation reserves** — Can create volatile charges and balance-sheet liabilities - **Impairment of property, plant and equipment** — May lead to non-cash write-downs - **Income taxes** — Can materially change net income and equity - **Hedging and foreign exchange** — Can affect operating results and comprehensive income - U.S. revenue deductions depend on estimates for rebates and chargebacks - Contingencies include litigation, regulatory and product-related claims - Impairment testing matters for plants, intangibles and goodwill - Hedging and foreign exchange can affect regional margins - Tax positions and valuation allowances can materially affect earnings --- *Last updated: 2026-09-24T11:53:05.400734+00:00*